The main cons are that Retatrutide is not yet approved for clinical use, gastrointestinal side effects are common during the first 8 to 12 weeks, a new safety signal called dysesthesia emerged in Phase 3, long-term data beyond 68 weeks is still limited, and weight tends to return after discontinuing treatment
Keep a detailed symptom diary documenting hunger levels, meal timing, food choices, sleep quality, and stress levels
These techniques are believed to provide a more comprehensive understanding of an individuals overall well-being
Sermorelin, by comparison, has primarily been used to stimulate physiological growth hormone production
Sometimes, additional sedation is offered